Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Objectives To determine the weight, body mass index (BMI), cardiometabolic, and gastrointestinal effects of glucagon-like peptide-1 (GLP-1) receptor agonists in children with obesity. Study design Web of Science, PubMed/MEDLINE, and Scopus databases from 01/01/1994-01/01/2021 for randomized control trials examining the weight, BMI, cardiometabolic, or gastrointestinal effects of GLP-1 receptor agonists in children and adolescents with obesity. Data were extracted by 2 independent surveyors and a random effects model was applied to meta-analyze generic inverse variance outcomes. Primary outcomes were related to weight and cardiometabolic profile, and secondary outcomes of interest were gastrointestinal-related treatment-emergent adverse events. Results Nine studies involving 574 participants were identified, of which 3 involved exenatide and 6 involved liraglutide. GLP-1 receptor agonists use caused a modest reduction in body weight (mean difference [MD] -1.50 [-2.50,-0.50] kg, I 2 64%), BMI (MD -1.24 [-1.71,-0.77] kg/m 2 , I 2 0%), and BMI z score (MD -0.14 [-0.23,-0.06], I 2 43%). Glycemic control was improved in children with proven insulin resistance (glycated hemoglobin A1c MD -1.05 [-1.93,-0.18] %, I 2 76%). Although no lipid profile improvements were noted, a modest decrease in systolic blood pressure was detected (MD -2.30 [-4.11,-0.49] mm Hg; I 2 0%). Finally, analysis of gastrointestinal-related treatment-emergent adverse events revealed an increased risk of nausea (risk ratio 2.11 [1.44, 3.09]; I 2 0%), without significant increases in other gastrointestinal symptoms. Conclusions This meta-analysis indicates that GLP-1 receptor agonists are safe and effective in modestly reducing weight, BMI, glycated hemoglobin A1c, and systolic blood pressure in children and adolescents with obesity in a clinical setting, albeit with increased rates of nausea. PROSPERO ID CRD42020195869.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Overall, GLP-1 receptor agonists appear to be safe in children and adolescents with obesity.[72][73][74]”
From Managing early-onset type 2 diabetes in the individual and at the population level (2025) · cites this paper as [72]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
Kelly, A. S., Auerbach, P., Barrientos-Perez, M., Gies, I., Hale, P. M., Marcus, C., Mastrandrea, L. D., Prabhu, N., & Arslanian, S. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916038 · Cited by 723
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672
Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60406-0 · Cited by 434
Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289
Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5
Kushner, R. F., Calanna, S., Davies, M., Dicker, D., Garvey, W. T., Goldman, B., Lingvay, I., Thomsen, M., Wadden, T. A., Wharton, S., et al. (2020) · Obesity · doi:10.1002/oby.22794 · Cited by 288
Research works printed but not linked: 27
- Di Cesare, 2019, The epidemiological burden of obesity in childhood: a worldwide epidemic requiring urgent action, BMC Med, 17, 212, 10.1186/s12916-019-1449-8 · DOI · Paper page
- Gori, 2017, Effectiveness of educational and lifestyle interventions to prevent paediatric obesity: systematic review and meta-analyses of randomized and non-randomized controlled trials, Obes Sci Pract, 3, 235, 10.1002/osp4.111 · DOI
- Cardel, 2020, Obesity treatment among adolescents: a review of current evidence and future directions, JAMA Pediatr, 174, 609, 10.1001/jamapediatrics.2020.0085 · DOI · Paper page
- Mead, 2016, Drug interventions for the treatment of obesity in children and adolescents, Cochrane Database Syst Rev, 11, CD012436
- Ryan, 2017, Recombinant incretin-secreting microbe improves metabolic dysfunction in high-fat diet fed rodents, Sci Rep, 7, 13523, 10.1038/s41598-017-14010-x · DOI
- Cole, 2000, Establishing a standard definition for child overweight and obesity worldwide: international survey, BMJ (Clinical research ed), 320, 1240, 10.1136/bmj.320.7244.1240 · DOI · Paper page
- Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration, BMJ (Clinical research ed), 339, b2700, 10.1136/bmj.b2700 · DOI · Paper page
- Booth, 2012, The nuts and bolts of PROSPERO: an international prospective register of systematic reviews, Syst Rev, 1, 2, 10.1186/2046-4053-1-2 · DOI · Paper page
- Mastrandrea, 2019, Liraglutide effects in a paediatric (7-11 y) population with obesity: a randomized, double-blind, placebo-controlled, short-term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics, Pediatr Obes, 14, e12495, 10.1111/ijpo.12495 · DOI · Paper page
- Kelly, 2013, The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial, JAMA Pediatr, 167, 355, 10.1001/jamapediatrics.2013.1045 · DOI · Paper page
- Kelly, 2012, Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study, Obesity (Silver Spring), 20, 364, 10.1038/oby.2011.337 · DOI · Paper page
- Danne, 2017, Liraglutide in an Adolescent population with obesity: a randomized, double-blind, placebo-controlled 5-week trial to assess safety, tolerability, and pharmacokinetics of liraglutide in adolescents aged 12-17 years, J Pediatr, 181, 146, 10.1016/j.jpeds.2016.10.076 · DOI · Paper page
- Weghuber, 2020, A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity, Pediatr Obes, 15, e12624, 10.1111/ijpo.12624 · DOI · Paper page
- Zhou, 2017, The effects of GLP-1 analogues on pre-diabetes of the children, Exp Ther Med, 13, 1426, 10.3892/etm.2017.4129 · DOI
- Klein, 2014, Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial, Diabetes Technol Ther, 16, 679, 10.1089/dia.2013.0366 · DOI · Paper page
- Tamborlane, 2019, Liraglutide in children and adolescents with type 2 diabetes, N Engl J Med, 381, 637, 10.1056/NEJMoa1903822 · DOI · Paper page
- Buse, 2013, Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study, Lancet, 381, 117, 10.1016/S0140-6736(12)61267-7 · DOI · Paper page
- Petroni, 2019, Combination of GLP-1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: a retrospective cohort study, Endocrinol Diabetes Metab, 2, e00082, 10.1002/edm2.82 · DOI
- Gerstein, 2019, Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial, Lancet, 394, 121, 10.1016/S0140-6736(19)31149-3 · DOI · Paper page
- Husain, 2019, Oral semaglutide and cardiovascular outcomes in patients with type 2 Diabetes, N Engl J Med, 381, 841, 10.1056/NEJMoa1901118 · DOI · Paper page
- Hasegawa, 2018, Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins, J Clin Lipidol, 12, 62, 10.1016/j.jacl.2017.11.006 · DOI
- Boniol, 2018, Incretin-based therapies and the short-term risk of pancreatic cancer: results from two retrospective cohort studies, Diabetes Care, 41, 286, 10.2337/dc17-0280 · DOI · Paper page
- Pinto, 2019, Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis, Sci Rep, 9, 2375, 10.1038/s41598-019-38956-2 · DOI · Paper page
- Li, 2020, Improving adherence to weight-loss medication (liraglutide 3.0 mg) using mobile phone text messaging and healthcare professional support, Obesity (Silver Spring), 28, 1889, 10.1002/oby.22930 · DOI
- Maljaei, 2020, Liraglutide for adolescents with obesity, N Engl J Med, 383, 1193
- Anker, 2020, Liraglutide for adolescents with obesity, N Engl J Med, 383, 1192, 10.1056/NEJMc2023284 · DOI
- Dube, 2020, Effect of liraglutide on food consumption, appetite sensations and eating behaviours in overweight people with type 1 diabetes, Diabetes Obes Metab, 22, 1417, 10.1111/dom.14050 · DOI · Paper page
Cited by
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300
Martin, S. S., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Barone Gibbs, B., Beaton, A. Z., Boehme, A. K., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001209 · Cited by 2,800
Martin, S. S., Aday, A. W., Allen, N. B., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Bansal, N., Beaton, A. Z., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001303 · Cited by 1,080
Rentzeperi, E., Pegiou, S., Koufakis, T., Grammatiki, M., & Kotsa, K. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030454 · Cited by 140
Luna-Marco, C., Iannantuoni, F., Hermo-Argibay, A., Devos, D., Salazar, J. D., Víctor, V. M., & Rovira-Llopis, S. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.01.015 · Cited by 114
Metadata
- Authors
- Ryan, P. M., Seltzer, S., Hayward, N. E., Rodriguez, D. A., Sless, R. T., & Hawkes, C. P.
- Venue
- The Journal of Pediatrics
- Publisher
- Elsevier BV
- Published
- 2021-09
- Volume
- 236
- Pages
- 137-147.e13
- ISSN
- 0022-3476 (ISSN-L)
- OpenAlex
- W3160819927
- Cited by
- 111
- References
- 15
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis. https://app.cochat.ai/papers/10.1016/j.jpeds.2021.05.009
- The paper
- Ryan, P. M., Seltzer, S., Hayward, N. E., Rodriguez, D. A., Sless, R. T., & Hawkes, C. P. (2021). Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis. The Journal of Pediatrics. https://doi.org/10.1016/j.jpeds.2021.05.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.